Greywolf Therapeutics
UK - Oxford
BiotechnologyFocus: Modulating ERAP1 and ERAP2 in immuno-oncology
Greywolf Therapeutics is a life sciences company focused on Modulating ERAP1 and ERAP2 in immuno-oncology.
Oncology
Funding Stage
SERIES B
Total Funding
$131M
Open Jobs
4
Open Jobs (4)
Interview Prep Quick Facts
Open Roles: 4 active jobs
Hiring Trend
Stable
4
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles